Landmark findings from Prof. Xinyang Hu and Prof. Yang Xu’s team at the Second Affiliated Hospital, Zhejiang University School of Medicine: heart failure therapy enters a new era of immune-targeted treatment.

On April 8, Beijing time, the research on engineered dendritic cells and immune tolerance in cardiac remodeling after heart failure was published in Nature.

Read the original article (opens in a new tab)Back to News & Innovation